Is DaVita a buy?
As of mid-2026, analyst consensus on DaVita (DVA) is mixed and suggests a cautious approach. Recent ratings indicate that 33% of analysts recommend a "Strong Buy," while 50% suggest "Holding" the stock, and 17% advise "Selling". There is currently no analyst consensus recommending a "Buy" or a "Strong Sell," reflecting significant uncertainty regarding the company's near-term growth prospects and operational stability. Investors should weigh these ratings against the company's recent operational headwinds—including challenges to patient trust and market perception—as well as the projections from firms like UBS that anticipate volume growth by 2029.
Related FAQs
Yes, "Dx" is a standard medical abbreviation used by healthcare professionals as shorthand for "diagnosis.
Warren Buffett does not hold shares of Diageo plc (trading under the ticker DEO) within Berkshire Hathaway's investment portfolio.
The Chief Executive Officer of Dollar Tree Inc. is compensated through a structured executive remuneration plan outlined in annual proxy filings. Total annual compensation for the chief executive officer typically ranges between 7.6 million and 9.
DaVita has undergone several rounds of layoffs and job cuts over the past few years, particularly between 2022 and 2024, as part of a multi-year restructuring and cost-cutting initiative.
As of July 2026, there is significant debate regarding the valuation of DaVita (DVA) stock.
DaVita (DVA) currently holds a consensus "Hold" rating among analysts. While 33% of analysts recommend a "Strong Buy," 50% suggest "Holding," and 17% advise "Selling.